T. Rowe Price Associates
PVLA

T. Rowe Price Associates’s Palvella Therapeutics PVLA Stock Holding History

T. Rowe Price Associates’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$97.6M Buy
638,868
+236,304
+59% +$28.7M 0.01% 701
2026
Q1 		$50.2M Buy
402,564
+398,474
+9,743% +$41.6M 0.01% 767
2025
Q4 		$429K Buy
4,090
+433
+12% +$36.9K ﹤0.01% 2463
2025
Q3 		$230K Buy
+3,657
New +$163K ﹤0.01% 2737

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

T. Rowe Price Associates's PVLA Position: Q2 2026 in Review

T. Rowe Price Associates increased its Palvella Therapeutics (PVLA) stake by 59% in Q2 2026, buying an estimated $28.7M and bringing the position to 638,868 shares worth $97.6M. The position accounts for 0.01% of the portfolio, ranked #701.

T. Rowe Price Associates first reported a position in PVLA in Q3 2025 and has held it in 4 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • T. Rowe Price Associates held 638,868 shares of Palvella Therapeutics worth $97.6M as of Q2 2026.
  • T. Rowe Price Associates bought 236,304 Palvella Therapeutics shares in Q2 2026, an estimated $28.7M.
  • Palvella Therapeutics made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #701 holding.
  • T. Rowe Price Associates first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.